Loading
A phase 2 trial of trilaciclib in lung cancer, run by Henan Cancer Hospital, now recruiting.
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib is a phase 2, interventional study registered as NCT06370416 by Henan Cancer Hospital, with a registry enrolment figure of 41 participants, started 2024-04-02 and due to reach its primary completion in 2026-01-30. Interventions recorded: Trilaciclib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: The incidence of grade ≥ 3 neutropenia during chemotherapy treatment. Lung eligibility wording from the registry: "* Patients with locally advanced and late stage (IIIB, IIIC, IV) NSCLC who have been confirmed by histopathology and cannot be surgically removed (without local symptoms (with or without brain metastasis)) have at least one measurable lesion that meets the RECIST 1". Sites: China. No results are recorded here; the registry entry is the source.
Shares Simcere Pharmaceutical, Trilaciclib, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Trilaciclib, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.